Celldex Therapeutics Inc. (CLDX): Today's Featured Drugs Laggard

Celldex Therapeutics ( CLDX) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.3%. By the end of trading, Celldex Therapeutics fell $0.40 (-2.0%) to $19.55 on average volume. Throughout the day, 1,715,986 shares of Celldex Therapeutics exchanged hands as compared to its average daily volume of 1,860,800 shares. The stock ranged in price between $19.20-$20.33 after having opened the day at $20.23 as compared to the previous trading day's close of $19.95. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 34.5%, Merrimack Pharmaceuticals ( MACK), down 28.0%, Inovio Pharmaceuticals ( INO), down 11.6% and CytRx Corporation ( CYTR), down 8.1%.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Celldex Therapeutics has a market cap of $1.6 billion and is part of the health care sector. Shares are up 197.3% year to date as of the close of trading on Wednesday. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and weak operating cash flow.

On the positive front, Rexahn Pharmaceuticals ( RNN), up 16.8%, Alnylam Pharmaceuticals ( ALNY), up 15.8%, Rockwell Medical ( RMTI), up 15.7% and Bacterin International Holdings ( BONE), up 14.9% , were all gainers within the drugs industry with Vertex Pharmaceuticals ( VRTX) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.
null